Esperion Therapeutics (NASDAQ:ESPR) Issues Earnings Results

Key Points

• Esperion Therapeutics reported a quarterly loss of ($0.02) earnings per share, surpassing expectations of ($0.17) by $0.15, with generated revenues of $82.39 million compared to estimates of $62.55 million.
• Following the earnings announcement, Esperion's stock rose by 8.7% to $1.62, with a market capitalization of $321.08 million.
• Several analysts have mixed ratings on the stock, with price targets ranging from $3.00 to $16.00, leading to a consensus rating of "Moderate Buy" with an average price target of $7.00.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.15, Zacks reports. The company had revenue of $82.39 million during the quarter, compared to analyst estimates of $62.55 million. Esperion Therapeutics had a negative return on equity of 0.91% and a negative net margin of 35.84%.

Esperion Therapeutics Stock Up 1.4%

Esperion Therapeutics stock traded up $0.03 during midday trading on Friday, reaching $1.84. The stock had a trading volume of 3,929,381 shares, compared to its average volume of 4,776,530. Esperion Therapeutics has a 12 month low of $0.69 and a 12 month high of $3.94. The firm's 50-day moving average price is $1.22 and its 200 day moving average price is $1.33. The firm has a market capitalization of $363.70 million, a PE ratio of -3.74 and a beta of 0.82.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently commented on the company. The Goldman Sachs Group lowered their target price on Esperion Therapeutics from $4.00 to $3.00 and set a "neutral" rating on the stock in a research note on Thursday, April 17th. HC Wainwright reiterated a "buy" rating and set a $16.00 target price on shares of Esperion Therapeutics in a research note on Tuesday, June 17th. Finally, Needham & Company LLC lowered their target price on Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Two investment analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $7.00.

Institutional Investors Weigh In On Esperion Therapeutics

A hedge fund recently bought a new stake in Esperion Therapeutics stock. Jones Financial Companies Lllp acquired a new stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) during the first quarter, according to its most recent 13F filing with the SEC. The fund acquired 192,743 shares of the biopharmaceutical company's stock, valued at approximately $278,000. Jones Financial Companies Lllp owned 0.10% of Esperion Therapeutics as of its most recent filing with the SEC. 47.39% of the stock is owned by institutional investors.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.